Top Page
Genmab
(NASDAQ:GMAB)
Genmab (GMAB) vs. SPDR S&P 500 ETF (SPY)
Genmab Business Overview & Revenue Model
Genmab Earnings Call Summary
Genmab Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 23.73B | 21.53B | 16.47B | 14.51B | 8.42B |
| Gross Profit | 21.76B | 20.54B | 16.25B | 14.51B | 8.42B |
| EBITDA | 8.43B | 9.70B | 5.95B | 7.35B | 4.18B |
| Net Income | 6.14B | 7.84B | 4.35B | 5.45B | 2.96B |
Balance Sheet | |||||
| Total Assets | 81.86B | 45.81B | 35.29B | 30.12B | 24.63B |
| Cash, Cash Equivalents and Short-Term Investments | 10.91B | 21.10B | 28.14B | 22.32B | 19.34B |
| Total Debt | 35.36B | 1.03B | 770.00M | 597.00M | 425.00M |
| Total Liabilities | 44.68B | 9.11B | 3.68B | 2.84B | 2.43B |
| Stockholders Equity | 37.18B | 36.70B | 31.61B | 27.28B | 22.20B |
Cash Flow | |||||
| Free Cash Flow | 7.33B | 7.58B | 7.00B | 3.60B | 1.98B |
| Operating Cash Flow | 7.56B | 7.77B | 7.38B | 3.91B | 2.23B |
| Investing Cash Flow | -35.99B | -9.91B | -1.28B | -2.76B | -961.00M |
| Financing Cash Flow | 30.55B | -3.92B | -606.00M | -789.00M | -420.00M |
Genmab Technical Analysis
Genmab Risk Analysis
Genmab Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
83 Outperform | $20.15B | 15.82 | 29.87% | ― | 18.09% | 3563.21% | |
75 Outperform | $26.66B | 25.94 | 11.48% | 2.23% | 3.72% | -31.46% | |
74 Outperform | $11.87B | 34.64 | 5.94% | ― | 12.31% | 60.21% | |
66 Neutral | $18.00B | 18.88 | 17.65% | ― | 24.98% | 127.06% | |
57 Neutral | $14.33B | -55.63 | ― | ― | 103.32% | 47.55% | |
53 Neutral | $26.51B | -41.92 | -2.94% | ― | 7.04% | -25.24% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Genmab Corporate Events
Genmab A/S, the Copenhagen-headquartered biotech group specializing in antibody-based therapies for cancer and serious diseases, operates across North America, Europe and Asia Pacific and has eight approved antibody medicines backed by a robust late-stage clinical pipeline. Its platforms span bispecific antibodies, antibody–drug conjugates and other next-generation modalities targeting transformative treatments.
On February 23, 2026, Genmab reported initial transactions under a share buy-back program launched on February 17, 2026 to repurchase up to 342,130 shares for up to DKK 725 million to meet Restricted Stock Unit obligations. Between February 18 and 20, 2026, the company bought 63,000 shares for a total of DKK 115.2 million, lifting its treasury position to 2,678,851 shares, or 4.17% of share capital, signaling ongoing capital management while remaining within EU market abuse “safe harbour” rules.
The most recent analyst rating on (GMAB) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
On February 20, 2026, Genmab A/S reported insider share transactions by a senior executive, complying with European market abuse regulations. The disclosure underscores the company’s adherence to transparency rules governing trading by managerial employees and their closely associated persons.
The filing details that Executive Vice President and Chief Financial Officer Anthony Pagano sold a total of 1,100 Genmab shares on February 19, 2026, on Nasdaq Copenhagen at an average price of DKK 1,810.10. While modest in size, the trade is formally reported under Article 19 of the Market Abuse Regulation, providing investors and regulators with timely visibility into management dealings in the stock.
The most recent analyst rating on (GMAB) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Genmab A/S has convened its 2026 Annual General Meeting for March 19, 2026, at the Copenhagen Marriott Hotel, where shareholders will review 2025 performance, vote on the audited annual report and compensation report, and consider board and auditor elections. The board proposes carrying forward the 2025 profit of USD 963 million to retained earnings, maintaining 2026 board and committee fees at 2025 levels, and re-electing six directors, preserving a diverse and largely independent board while also seeking approval to reduce share capital via cancellation of treasury shares, which would modestly enhance capital structure efficiency and per-share metrics.
Shareholders will also vote on reappointing Deloitte as auditor, including a limited assurance mandate on sustainability statements, underscoring Genmab’s focus on governance and ESG disclosure. The meeting agenda, including authorization of the chair to implement resolutions, reflects a continuation of the company’s current strategic and governance framework, with no major shifts in capital allocation but a clear emphasis on stability, board continuity and incremental capital optimization through the proposed share capital reduction.
The most recent analyst rating on (GMAB) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Genmab A/S, the Copenhagen-based biotechnology group specializing in antibody medicines for oncology and other serious illnesses, has built a portfolio that includes bispecific antibodies, antibody-drug conjugates and immune-modulating antibodies. The company’s science underpins eight approved antibody drugs and supports a late-stage clinical pipeline of both partnered and wholly owned programs targeting transformative treatments.
On February 17, 2026, Genmab announced the launch of a share buy-back program to meet obligations under its Restricted Stock Unit scheme. Beginning February 18 and running no later than March 31, 2026, the company may repurchase up to 342,130 shares for a maximum of 725 million DKK via Danske Bank under a non-discretionary mandate, a move that modestly increases potential capital returns while managing dilution and adds to the 2,615,851 treasury shares already held.
The buy-back will be executed on Nasdaq Copenhagen and other multilateral trading facilities in line with EU “Safe Harbour” rules governing price and volume, including daily caps tied to recent trading volumes. Genmab retains the right to suspend or terminate the program and will provide weekly disclosures on repurchases, offering investors transparency on execution and the pace of treasury share accumulation supporting its equity compensation strategy.
The most recent analyst rating on (GMAB) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
On February 3, 2026, Genmab A/S filed a Form 6-K in the United States detailing an updated set of Articles of Association adopted on January 29, 2026, which formalize key elements of the company’s corporate structure and capital framework. The revised articles confirm the company’s current share capital of DKK 64,238,408 and grant the board authority, through March 12, 2029, to increase share capital by up to a nominal DKK 6.6 million with or without pre-emptive rights, issue warrants and convertible debt for employees and investors under specified caps, and adjust the articles accordingly, measures that collectively give management material flexibility to fund growth and incentivize staff while potentially diluting existing shareholders over time.
The most recent analyst rating on (GMAB) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
On January 29, 2026, Genmab A/S announced that its board had granted 32,806 restricted stock units and 34,307 warrants to employees of the company and its subsidiaries as part of its long-term incentive programs. The RSUs, each representing the conditional right to one Genmab share with a fair value equal to the January 29 closing price of DKK 2,067, will vest after three years subject to program conditions, while the cost-free warrants, also struck at DKK 2,067 per share and valued at DKK 658.81 using Black-Scholes, will vest after three years and remain exercisable until seven years from the grant date. The move underscores Genmab’s continued use of equity-based compensation to align employees with shareholder interests and support retention in a competitive global biotech talent market.
The most recent analyst rating on (GMAB) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
On January 21, 2026, Genmab reported that 2025 worldwide net trade sales of the multiple myeloma therapy DARZALEX (daratumumab), including its subcutaneous formulation DARZALEX FASPRO, reached USD 14.351 billion, according to figures from license partner Johnson & Johnson’s Janssen unit. Sales totaled USD 8.266 billion in the United States and USD 6.085 billion in the rest of the world, and Genmab earns royalties on all global DARZALEX sales under its exclusive worldwide license agreement with J&J, underscoring the product’s continued commercial strength and its importance as a major revenue driver for the Danish biotech.
The most recent analyst rating on (GMAB) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
On January 16, 2026, Genmab reported topline Phase 3 results from its global EPCORE DLBCL-1 trial of subcutaneous bispecific antibody epcoritamab in patients with relapsed or refractory diffuse large B‑cell lymphoma who were ineligible for high‑dose chemotherapy and autologous stem cell transplant. The study, which enrolled 483 patients and compared epcoritamab monotherapy with standard chemo‑immunotherapy regimens R‑GemOx or BR, showed a statistically significant improvement in progression‑free survival and gains in complete response rate, duration of response and time to next treatment, while overall survival did not reach statistical significance and safety findings appeared consistent with the known profile. Genmab and partner AbbVie plan to discuss the data with global regulators and continue to position epcoritamab as a potential core therapy across B‑cell malignancies, supported by multiple ongoing Phase 3 programs in both frontline and relapsed DLBCL and follicular lymphoma that could further expand its clinical and commercial footprint if successful.
The most recent analyst rating on (GMAB) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
On December 29, 2025, Genmab announced it would discontinue further clinical development of acasunlimab following a portfolio review and assessment of a more competitive market landscape. Although the company described the drug’s clinical profile to date as encouraging, management said it will redirect resources toward late-stage programs it sees as having higher potential impact, notably EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan (Rina-S). The move underscores Genmab’s disciplined approach to portfolio prioritization and capital allocation, and the company emphasized that the decision will not affect its full-year 2025 financial guidance, reassuring investors that its broader pipeline momentum and financial outlook remain intact.
The most recent analyst rating on (GMAB) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
On December 12, 2025, Genmab A/S announced the successful completion of its tender offer to acquire all outstanding common shares of Merus N.V. for $97 per share, marking a significant step in its strategy to become a global biotechnology leader. This acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio, and is expected to be accretive to the company’s EBITDA by the end of 2029, with potential multi-billion-dollar annual revenue thereafter.
The most recent analyst rating on (GMAB) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
On December 1, 2025, Genmab A/S announced transactions involving shares and linked securities conducted by its managerial employees and their closely associated persons. These transactions, which were acquisitions due to the vesting of restricted stock units, reflect internal movements within the company’s stock holdings. The disclosure is in compliance with market regulations and highlights the vested interests of key personnel in Genmab’s operational success.
The most recent analyst rating on (GMAB) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
On November 26, 2025, Genmab A/S announced updates to its Articles of Association, which include authorizations for the Board of Directors to increase the company’s share capital and issue warrants and convertible debt instruments. These changes are aimed at providing financial flexibility and supporting the company’s growth strategy, potentially impacting shareholder value and market positioning.
The most recent analyst rating on (GMAB) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.